phosphonic acid has been researched along with Secondary Hyperparathyroidism in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akiba, T; Akizawa, T; Fukagawa, M; Kuwabara, M; Shigematsu, T; Tsuchiya, A; Yokoyama, K; Yoshikawa, K | 1 |
| Benedik, M; Bos, WJ; Cabezas-Rodriguez, I; Cannata-Andia, JB; Carrero, JJ; Covic, A; Fernández-Martín, JL; Ferreira, A; Floege, J; Goldsmith, D; Gorriz, JL; Ketteler, M; Kramar, R; Locatelli, F; London, G; Martin, PY; Martínez-Camblor, P; Memmos, D; Nagy, J; Naves-Díaz, M; Pavlovic, D; Rodríguez-García, M; Rutkowski, B; Sánchez-Alvarez, JE; Teplan, V; Tielemans, C; Verbeelen, D; Wüthrich, RP | 1 |
1 trial(s) available for phosphonic acid and Secondary Hyperparathyroidism
| Article | Year |
|---|---|
COSMOS: the dialysis scenario of CKD-MBD in Europe.
Topics: Aged; Biomarkers; Bone Diseases, Metabolic; Calcium; Europe; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Function Tests; Male; Parathyroid Hormone; Phosphorous Acids; Prognosis; Prospective Studies; Renal Dialysis; Risk Factors | 2013 |
1 other study(ies) available for phosphonic acid and Secondary Hyperparathyroidism
| Article | Year |
|---|---|
Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan.
Topics: Administration, Intravenous; Aged; Alkaline Phosphatase; Calcimimetic Agents; Calcium; Female; Gastrointestinal Diseases; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Japan; Male; Middle Aged; Parathyroid Hormone; Peptides; Phosphorous Acids; Product Surveillance, Postmarketing; Renal Dialysis; Renal Insufficiency, Chronic | 2021 |